Catalent Expert To Present On Technology Delivery, Formulation and Manufacturing at 2012 Drug Delivery Partnerships Conference
Somerset, NJ, January 18, 2012 — Karen MacGregor, PhD, R&D Platform Director, Controlled Release Technologies for Catalent Pharma Solutions, will present “Recent Advances in Oral Disintegrating Tablets and Bi-Layer Tablets Technologies for Better Treatments” on January 27, at Drug Delivery Partnerships 2012 in Las Vegas, NV. The Drug Delivery Partnerships conference focuses on collaborations to drive progress in drug delivery through uncovering new partners, new drug delivery technologies and new formulation development strategies to accelerate drugs to market and lengthen lifecycles for long-term profitability.
- Dr. MacGregor’s presentation will cover the following topics:
- How partnerships in delivery technology, formulation and marketing drive more products to market faster with better treatments;
- Catalent’s proven ability to improve therapeutic profiles through drug delivery enhancements, i.e. Zydis® Fast-Dissolve Tablets, including innovative formulation of Grazax® as the first once-daily, oral tablet allergy immunotherapy treatment for allergy sufferers;
- Business case examples of value creation, and
- New advancements for the development of difficult to manufacture molecules with the introduction of OSDrC®OptiDose™ Drug Delivery Technology.
As R&D Platform Director, Dr. MacGregor brings to Catalent nearly 18 years of pharmaceutical industry experience. Prior to this role, Dr. MacGregor served as the Director of Oral Product Development (Modified Release Technologies) and European Director of Project Management for Catalent Pharma Solutions. Throughout Dr. MacGregor’s career, she has held functional and leadership roles in Rhone Poulenc Rorer, Aventis, CCL Pharmaceuticals and Cardinal Health where she led technical teams in areas of formulation/process development and in operational technical support. Dr. MacGregor is a registered pharmacist in the United Kingdom, holds a doctorate from DeMontfort University in England and an MBA from the Open University.
For more information on this event, please visit: www.iirusa.com/ddp/welcome .
To schedule an interview with the above mentioned presenter, during Drug Delivery Partnerships 2012 or after, please contact Patricia McGee at email@example.com .
To receive a copy of this presentation after the event, please visit us at www.catalent.com .
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,000 people at 20+ facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.
more products. better treatments. reliably supplied.™
Zydis® is a registered trademark of Catalent Pharma Solutions, Inc.
OptiDose™ is a trademark of Catalent Pharma Solutions, Inc.
Grazax® is a registered trademark of ALK-Abello
OSDrC® is a registered trademark of Sanwa Kagaku Kenkyusho Co., Ltd